Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Redx Pharma looks forward to phase II trial results in 2023

Published 20/12/2022, 08:12
Updated 20/12/2022, 08:41
© Reuters.  Redx Pharma looks forward to phase II trial results in 2023

© Reuters. Redx Pharma looks forward to phase II trial results in 2023

Proactive Investors - Redx Pharma Plc (LON:REDX) said its recent fundraising has given it a cash runway into 2024 as it released results showing revenues also grew strongly in the year to end-September 2022.

The biotech has two drugs going through phase II clinical trials this year, RXC004 for Wnt-ligand dependent cancers and RXC007 for idiopathic pulmonary fibrosis (IPF), while earlier in the year it nominated a third candidate, RXC008 for fibrostenotic Crohn's disease, as its next clinical development candidate.

In the half-year results statement, Lisa Anson, RedX chief executive, said: "I am very proud of our track record of consistently generating differentiated drug candidates and excited by the potential of the five clinical molecules we have discovered to treat significant unmet needs in cancer and fibrosis.

“Our two lead assets, RXC004 and RXC007, are now in Phase 2 clinical studies, and we look forward to reporting results from these studies during the next calendar year."

"Importantly, given the current economic and market backdrop, during the period we were also able to raise significant additional capital to bolster our balance sheet. This provides us with a cash runway into 2024 that will allow us to deliver multiple value-inflection points," she added.

Revenues for the year rose to £18.7mln (H1 2021: £10mln) including milestone payments of £10.7mln with research awards and services chipping in £8mln (H1 2021: £5mln).

Losses for the year were reduced to £18mln (H1 2021: £21mln) even though R&D expenditure rose to £34.4mln (H1 2021: £21.5mln).

Redx had a cash balance at the period end of £53.9mln.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.